ICH M2 EWG Work Plan January 28, 2022

Topic Adoption date: 1994

Rapporteur: Ms. Mary Ann Slack - FDA, United States & Dr. Mihoko Okada - MHLW/PMDA,

Japan (Co-Rapporteurs)

Regulatory Chair: Dr. Stephan Jaermann - Swissmedic, Switzerland

Last Face-to-Face Meeting: Amsterdam, the Netherlands (June 2019)

1. Key milestones

1.a. Current status of key milestones

| Past completion date | Milestone |
|----------------------|--|
| Nov. 2021 | MC presentation on Streamlined Standards Development Process submitted to the Secretariat. |

1.b. Future anticipated key milestones

| Expected future completion date | Milestone | |
|---------------------------------|---|--|
| Jun. 2022 | Report on the dedicated sessions on the potential to innovate regulatory process through technology | |
| Jun. 2022 | Assessment of a potential next step or project opportunity | |
| Jun. 2022 | If needed, revised recommendations to streamline ICH standards development process | |

${\bf 2.}\ Timeline\ for\ specific\ tasks$

(note – periodic administrative activities such as SDO liaison activities are not included)

| Beginning | | | | | | |
|------------------------------|------------|---|--|--|--|--|
| date | End date | Task / Activity | Details | | | |
| ESTRI Recommendation | | | | | | |
| Dec. 2021 | Jun. 2022 | 2D Bar code | Develop recommendation for 2D barcodes usage in submissions. | | | |
| Project Opportunity Proposal | | | | | | |
| (recurring activity) | | Evaluate new ICH topics concept papers for understanding – stage 1 | Talk with topic experts in each EWG at Step 1 to explore potential technological risks or opportunities | | | |
| (recurring activity) | | Evaluate ICH topics at step 3 or 4 for technical risks and opportunities – stage 2 | Review Step 3-4 documents for technical risks and opportunities; aggregate and discuss at next F2F meeting; discuss findings with EWG Rapporteurs | | | |
| Dec. 2021 | Jun. 2022 | Ensure that the ICH topics evaluation is clear to EWGs | Work with Secretariat to ensure that the ICH topics evaluation is clear in ICH step procedure | | | |
| Supportive Act | tivities | | | | | |
| Oct. 2021 | Jun. 2022 | Develop report on the dedicated sessions on the potential to innovate regulatory process through technology | Summarize the multiple dedicated sessions on the potential innovations to electronic exchange, data sharing and computation that could innovate the regulatory process | | | |
| Dec. 2021 | Jun. 2022 | If needed, revise recommendations to streamline ICH standards development process based on ICH MC input. | Review and Revise recommendations to streamline ICH standards development process based on the paper study and ICH MC input | | | |
| Jul. 2020 | Continuous | M11-M2 subgroup continues to refine the Technical Description | M11 and M2 subgroup continue to refine the Technical Description version 1 for Clinical electronic | | | |

| | | version 1 (phase 1 derivable) | Structured Harmonized Protocol (CeSHarP) based on M11 work progresses. |
|-----------|------------|---|---|
| Jan. 2020 | Continuous | Monitor FHIR development and maturity progress that is relevant to ICH | Monitor FHIR development and maturity progress that is relevant for ICH purposes with updates to the MC as significant progress occurs. |